Canagliflozin Powder

Xi'an Sonwu Biotech Co., Ltd. is one of the most professional manufacturers and suppliers of canagliflozin powder in China. We warmly welcome yuo to wholesale bulk canagliflozin powder for sale here from our factory. Quality products and reasonable price are available.

SGLT2 Inhibitor Canagliflozin
Canagliflozin powder belongs to sodium-glucose cotransporter two inhibitors or SGLT2 inhibitors. SGLT2 is an essential protein responsible for glucose reabsorption in the renal tubules. When the blood sugar level is higher than usual, the kidneys will over-filter the blood to excrete the glucose in the blood and prevent the blood sugar from continuing to rise. However, when the reabsorption capacity of the glomeruli reaches saturation, glucose above this limit begins to be excreted in the urine. SGLT2 plays an essential role in the body by helping the kidneys reabsorb filtered glucose, but if the kidneys are over the filter, it can lead to increased excretion of glucose, known as glycosuria. Canagliflozin can inhibit SGLT2, which can reduce the absorption of glucose by the kidneys so that the glucose in the body is excreted in the urine, then reducing blood sugar levels.
At present, a large number of evidence-based medicine has confirmed that canagliflozin can protect the cardiovascular and improve the prognosis of kidney disease while reducing blood sugar and reduce the effect of proteinuria. Clinically, patients with diabetic nephropathy are often recommended to use canagliflozin to lower blood sugar while protecting the kidneys and improving the prognosis of the kidneys. For patients without diabetic nephropathy but with clinical diabetes and other glomerular diseases, canagliflozin can also be considered if renal function permits. After all, it can improve cardiovascular and renal prognosis. It is most notable for weight loss and few hypoglycemic events and has great promise. If you are interested in raw canagliflozin, you can contact Xi'an Sonwu, Xi'an Sonwu will give you a professional answer about this product.

Certificate of Analysis

Where To Buy Canagliflozin
Xi'an Sonwu Biotech Co. ltd. is a manufacturer and distributor with over ten years of experience. It has extensive and stable cooperation with countries worldwide in the Americas, Asia, Europe, and Oceania. Xi'an Sonwu has always insisted on product quality first. Serving every customer well and satisfying every customer is Xi'an Sonwu's pursuit. Xi'an Sonwu strictly controls every step, from the selection of raw materials, and pursues high-quality products from all aspects, such as material selection, manufacturing, sample testing, and personnel professionalism. In addition, Xi'an Sonwu strives to handle every detail to minimize costs and allow customers to get products with high-cost performance. Based on these, customers have given good feedback on the product. So if you need canagliflozin weight loss powder, please contact Xi'an Sonwu.
Xi'an Sonwu ultimately ensures the product's quality and supplies the samples. Here is the quantity.

Customers' Good Comment

How Does Canagliflozin Lower Blood Sugar
Inhibits sodium-glucose cotransporter
As an SGLT2 inhibitor, canagliflozin mainly acts on SGLT2, reducing proximal renal tubule glucose reabsorption to 100-130 g/d, and increasing urinary glucose excretion to 50-80 g/d, thereby correcting T2DM patient's blood sugar. In an animal experiment, after administering canagliflozin to rats for 24 hours, a high concentration of canagliflozin was detected in the small intestine, indicating that canagliflozin may have an inhibitory effect on SGLT1. Its mechanism may be that canagliflozin inhibits small intestinal SGLT1, temporarily inhibits intestinal glucose absorption, increases postprandial total glucagon-like peptide-1 (GLP-1) levels, temporarily reduces postprandial insulin-stimulating polypeptide levels and reduces postprandial Insulin secretion, thereby improving blood sugar control. Therefore, canagliflozin not only improves insulin resistance by inhibiting renal SGLT2 but also partially inhibits SGLT1 to delay intestinal glucose absorption and reduce postprandial blood glucose rise, which has dual effects of α-glucosidase inhibitor-like development and renal mechanism.

Improve islet function
Blood glucose levels are regulated by insulin resistance and β-cell function, and the reduction of adiponectin levels caused by visceral fat accumulation is an essential mechanism of insulin resistance. Canagliflozin can increase serum adiponectin levels and reduce visceral adipose tissue and ectopic fat accumulation, alleviating insulin resistance. Patients with higher body mass index (BMI) increased glucagon or FFAs levels, decreased body weight, and reduced insulin resistance after canagliflozin treatment; patients with lower BMI were treated with canagliflozin due to improved blood sugar; Insulin's role in promoting fat synthesis and urinary excretion of energy (glucose) increase, resulting in increased body mass.

Beta cell proliferation
Hyperglycemia has many metabolic pathways during glycolysis that can damage peripheral nerves and cause diabetic polyneuropathy. In addition to sensory neuropathy, the number of tiny fibers of autonomic nerves in the pancreas may also decrease, decreasing the volume density of pancreatic β cells. After canagliflozin treatment, the parasympathetic nerve density in the islets and the nerve fiber density in the epidermis increased, which improved the loss of unmyelinated tiny fibers in the early stage of DPN, thereby increasing Vβ.

What Is Canagliflozin Used For

1. Weight loss and lipid-lowering effects
Canagliflozin powder can significantly reduce body weight in overweight or obese T2DM patients, and with the prolongation of treatment time, canagliflozin can continue to play a role in reducing body weight. The early weight loss of canagliflozin is caused by the excretion of fluid caused by the natriuretic effect of canagliflozin. The later weight loss is due to the reduction of calories and the resulting reduction of fat mass.
After canagliflozin weight loss powder treatment, abdominal visceral fat and subcutaneous fat decreased, and adiponectin levels increased, indicating that canagliflozin can reduce obesity-induced adipose tissue inflammatory response. In addition, canagliflozin inhibits the inflammatory response of the nervous system and skeletal muscle by excreting glucose in the urine, reducing glucose toxicity, and improving obesity and obesity-related metabolic disorders. Canagliflozin increased the content of mitochondrial DNA in white adipose tissue and up-regulated the expression of mitochondrial genes in adipocytes such as PGC-1α, NRF1, COX5b, CPT1b, Acadm, and PPARα in adipocytes. It directly affects fat cells' energy consumption, improves the mitochondrial function and fatty acid oxidation of fat tissue and fat cells, reduces body weight, fat mass, and WAT weight, inhibits fat cell hypertrophy, and improves blood sugar and blood lipid metabolism disorders caused by obesity.

2. Antihypertensive effect
T2DM is often accompanied by high blood pressure, a significant risk factor for complications such as heart failure and aggravated diabetic kidney damage. Controlling high blood pressure is the main target for reducing cardiovascular and renal risks. Canagliflozin can significantly lower systolic blood pressure. Under hyperglycemia, excess glucose enters renal proximal tubular cells through SGLT2, stimulates the production of angiotensinogen in the kidney, activates the renin-angiotensin system in the kidney, increases the level of angiotensin II in the kidney, causes Sodium retention, increased arterial pressure. Canagliflozin reduces the generation of ROS in PTC and increases the expression of AGT in the kidney by blocking SGLT2, inhibits oxidative stress in the kidney, and attenuates tubulointerstitial monocyte/macrophage infiltration, tubular fibrosis, and renal cortical Cell proliferation, thereby lowering blood pressure.

3. Lower uric acid
Patients with type 2 diabetes are usually accompanied by hyperuricemia, resulting in damage to multiple target organs, causing coronary heart disease, hypertension, stroke, and other complications, and accelerating kidney damage. Canagliflozin can significantly reduce serum uric acid levels and halve the risk of first-episode and recurrent gout adverse events. The mechanism by which SGLT2 inhibitors reduce uric acid may be to increase luminal glucose concentration, stimulate excretion of uric acid in proximal tubules mediated by GLUT9 isoform two or any other transporter, and inhibit uric acid reabsorption mediated by GLUT9 isoform 2, Thereby reducing blood uric acid levels.

4. Cardiovascular protection
Diabetic patients have a variety of cardiovascular risk factors, and cardiovascular disease has become the leading cause of death in T2DM patients. Therefore, treatment should not only control blood sugar within a reasonable range but also control cardiovascular and other risk factors. Canagliflozin significantly reduced the risk of cardiovascular death and non-fatal myocardial infarction.
Endothelial cell dysfunction is the primary pathogenesis of diabetic vascular disease. Canagliflozin is an inhibitor of EC proliferation and DNA synthesis. It stimulates the expression of HO-1, an antioxidant enzyme in vascular smooth muscle cells through the ROS-Nrf2 pathway, and inhibits angiogenesis. It can promote the Akt-eNOS path, inhibit p38MAPK and advanced glycation end product-advanced glycation end product receptor system, reduce the expression of inflammatory molecules and oxidative stress, alleviate endothelial cell dysfunction, vascular inflammatory response, and arterial development of atherosclerosis.

Factory
1. Xi'an Sonwu Biotech Co., Ltd has its factory to produce, manufacture and store the products, so have adequate Stock. Xi'an Sonwu has a well-ordered, clean, and tidy production department. Under Xi'an Sonwu, researchers can continuously develop high-quality new products.
2. Xi'an Sonwu has strict requirements on personnel allocation from production and testing to sales. To ensure that each product is escorted, rigorous data support and after-sales service are provided.

Certificate

Packing

Logistics

Besides guaranteeing the product, the other most important thing is customers can receive the goods smoothly. So, Xi'an Sonwu supplies all kinds of couriers according to different needs.

FAQ
The recommended starting dose of canagliflozin weight loss powder is 100 mg once before the first meal of the day. For patients who tolerate this product's 100mg once-daily dose, the estimated glomerular filtration rate is≥ 60mL/min/1.73m2 and need additional glycemic control; the dose can be increased to 300mg once a day. Please follow the doctor's advice for details.
For patients with hepatic insufficiency, patients with mild to moderate hepatic insufficiency will not affect the use, and those with severe hepatic insufficiency are not recommended.
Canagliflozin itself does not increase the risk of hypoglycemia. When combined with metformin, DPP4 inhibitors, and other drugs, the risk of hypoglycemia is also shallow. However, when combined with sulfonylureas and insulin, it may increase hypoglycemia risks and deserve special attention. For the elderly taking such drugs, especially those with decreased renal function and glomerular filtration rate less than 60, attention should also be paid to the risk of hypotension caused by such medications.
If you want to know a canagliflozin manufacturer, you can contact Xi'an Sonwu. Click the email then you get high-quality canagliflozin powder.
Email: sales@sonwu.com

Hot Tags: canagliflozin powder, China, suppliers, manufacturers, factory, wholesale, buy, price, bulk, pure, raw, supply, for sale, Methylene Blue Powder, Gefitinib powder, naftopidil powder, L Glutamine Powder, Mitoxantrone HCl, Doramectin Powder